Previous Article | Next Article ![]()
Infection and Immunity, May 1999, p. 2561-2566, Vol. 67, No. 5
Departments of
Dermatology,1
Pathology,2 and Clinical
Genetics,4 Karolinska Hospital, S-17176
Stockholm, Sweden, and Granulocyte Research Laboratory,
Department of Hematology, Rigshospitalet, Copenhagen DK-2100,
Denmark3
Received 15 October 1998/Returned for modification 25 November
1998/Accepted 6 January 1999
Peptide antibiotics are widespread in nature and, by providing a
rapid first line of defense, may be key players in the innate immune
system. Although epithelia are the main barriers shielding the internal
environment from microorganisms, the role for peptide antibiotics in
epithelial protection is unclear. We recently reported that the human
cationic antimicrobial protein hCAP18, the precursor of the
antimicrobial peptide called LL-37, is not expressed by normal human
keratinocytes but is induced in various inflammatory skin disorders. In
the present study we demonstrate that hCAP18 is consistently expressed
at both mRNA and protein levels in squamous epithelia of the mouth,
tongue, esophagus, cervix, and vagina in humans. The gene for hCAP18
contains promoter elements that are potentially regulated by
interleukin-6, and our data further show a colocalization between
interleukin-6 and hCAP18 expression in these tissues. Our finding that
hCAP18 is widely produced in squamous epithelia suggests a role for
this peptide in epithelial antimicrobial defense. Furthermore,
colocalization with interleukin-6 indicates a potential local mechanism
for the upregulation of hCAP18 at the epithelial surfaces.
Peptide antibiotics may serve a key
protective role in the host defense. They are participants in the
innate immune system (nonadaptive immune system), acting as effector
molecules with the capacity to kill a broad spectrum of microorganisms
(6). In contrast to highly specific adaptive immunity, the
innate immune system provides a rapid and nonspecific response and
thereby contributes to the first line of defense. The first peptide
antibiotics were discovered in the 1980s when cecropins were isolated
from insects (25) and defensins were isolated from rabbit
macrophages (24). Numerous antimicrobial peptide antibiotics
occur in nature, and over a dozen have been identified in humans,
including several salivary histatins, lactoferricin, six hCAP18, the C-terminal domain of which is called LL-37, has been
isolated from specific granules of human neutrophil granulocytes and is
structurally distinct from the defensins (9, 15). hCAP18
belongs to the cathelicidin family of proteins characterized by a
conserved cathelin proregion and a variable antibacterial peptide in
the C-terminal domain. The gene for hCAP18, named CAMP, is the only
member of the cathelicidin family so far identified in humans. CAMP
appears to have a restricted spatial expression pattern and has thus
far been reported to be produced constitutively only in bone marrow, in
testis, and in airway epithelium and to be upregulated in skin
epithelium in association with inflammation (1, 5, 12). The
promoter region of the CAMP gene contains potential binding sites for
the transcription factors, the acute-phase response factor, and the
nuclear factor for interleukin-6 (IL-6) (15). IL-6 regulates
the activation of these two transcription factors, indicating that this
cytokine may play an important role in modulating CAMP gene expression
(2, 3). IL-6 is a multifunctional cytokine involved in
various inflammatory responses and is consistently found in association
with infectious processes (22).
Epithelia serve a critical role in separating the organism from the
environment. In addition to providing fundamental physical and
mechanical shields, epithelia function as active immunological organs
by presenting antigens and producing cytokines (7), and
epithelia are, in fact, able to produce antibacterial peptides (5,
16, 23). Thus, different members of the defensin family are
encountered in several human epithelia and are induced by human
keratinocytes in culture (16, 19, 30); a recent study by
Bals et al. described the expression of hCAP18 in airway epithelium (5). We have previously shown that hCAP18 is produced in
human epidermis in association with a variety of inflammatory disorders (12). These findings led us to suggest that hCAP18, although not constitutively expressed in the epidermis, is induced
nonspecifically in response to inflammation. The present study further
delineates the expression of hCAP18 in nonkeratinizing human squamous
epithelia, and we report here that hCAP18 was consistently expressed at
both mRNA and peptide levels in squamous epithelia of the buccal
mucosa, tongue, esophagus, cervix, and vagina. In all tissues the
expression of hCAP18 colocalized with the immunoreactivity for IL-6, a
finding which is noteworthy in view of the potential role for this
cytokine in modulating hCAP18 gene expression. Our findings suggest the presence of a powerful antimicrobial defense system at the epithelial interfaces and a putative local mechanism for its regulation.
Tissues.
Formalin-fixed and paraffin-embedded archival human
tissues, including samples from the buccal mucosa (n = 3), tongue (n = 2), esophagus (n = 2), cervix (n = 5), and vagina (n = 3), were obtained from the Department of Pathology, Karolinska
Hospital, Stockholm, Sweden. All material was obtained at surgery
(Table 1).
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
The Human Cationic Antimicrobial Protein (hCAP18), a Peptide
Antibiotic, Is Widely Expressed in Human Squamous Epithelia and
Colocalizes with Interleukin-6
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-defensins,
two
-defensins, and the human cationic antimicrobial protein hCAP18.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
TABLE 1.
Clinical patient data
Preparation of RNA probes. A 435-bp hCAP18 full-length cDNA (9) was subcloned in Bluescript KS 11 and, after linearization with BamHI and EcoRI, was used as a template for in vitro transcription to generate 35S-labeled antisense and sense probes. After transcription, the RNA probes were ultrafiltered (Micron 100; Amicon, Inc., Beverly, Mass.) before hybridization.
Northern analysis. To ascertain the specificity of the probe derived from full-length hCAP18 cDNA, we performed a Northern analysis by using a multiple-tissue Northern blot containing poly(A)+ RNA from samples from the stomach, thyroid, spinal cord, lymph node, trachea, adrenal gland, and bone marrow (Clontech Laboratories). The quality of the blot was confirmed through hybridization with cDNA probes detecting ubiquitously expressed transcripts. Prehybridization and hybridization with a randomly 32P-labeled cDNA probe for hCAP18 were performed according to the manufacturer's instructions. The blots were washed at 0.1× SSC (1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-0.1% sodium dodecyl sulfate at 65% and, after overnight autoradiography, were evaluated with a phosphorimager system (Fuji Bas 1000).
In situ hybridization. In situ hybridization was performed essentially as described earlier (26). Briefly, 5-µm sections were hybridized overnight with 2.5 × 106 to 5.0 × 106 cpm of 35S-labeled RNA probes at 55°C. After hybridization, the slides were washed under stringent conditions that included incubation with 50 µg of RNase A (Sigma) per ml for 30 min at 37°C and were processed for autoradiography. Autoradiographic exposure was for 3 to 4 weeks.
Immunohistochemistry. (i) hCAP18. Protein A-purified antibodies raised in rabbits against recombinant hCAP18 were used at a 1:500 dilution (27). Deparaffinized, rehydrated sections were treated with 1% H2O2 in methanol for 30 min at room temperature to quench endogenous peroxidase activity. After being rinsed in phosphate-buffered saline, the sections were microwave treated twice for 5 min. All sections were stained according to the indirect peroxidase method (17) by using a Vectastain ABC Elite Kit (Vector Laboratories) and following the manufacturer's instructions. Control sections from the same tissues were similarly processed except that no hCAP18 antibody was added. As an additional control, we performed immunohistochemistry as described above with rabbit serum diluted 1:500 (Dako, Copenhagen, Denmark) instead of primary hCAP18 antibody.
(ii) Immunoadsorption of hCAP18. To ascertain the specificity of the immunostaining, we performed immunoadsorption, adding 10 µl of the hCAP18 recombinant protein (27) to 150 µl of a 1:500 dilution of anti-hCAP18 antibody. The final concentration of the hCAP18 recombinant peptide in the reaction mixture was 33 µg/ml. The mixture was preincubated at 4°C overnight with gentle shaking prior to immunohistochemical analyses according to the protocol described above. Control sections were processed according to the same protocol except that no peptide was added to adsorb the antibody.
(iii) IL-6. A monoclonal IL-6 antibody diluted 1:50 (Janssen, Beerse, Belgium) (8) was used for the immunostaining on serial sections from the same tissues. The sections were stained according to the indirect peroxidase method described above.
| |
RESULTS |
|---|
|
|
|---|
Probe specificity.
Northern blot analysis confirmed the
specificity of the hCAP18 probe. A single prominent message of less
than 1 kb was detected specifically in bone marrow (Fig.
1).
|
hCAP18 mRNA and peptide are expressed in human squamous epithelia. All tissues were reviewed by an experienced pathologist and were evaluated as listed in Table 1. In all tissues there was a positive signal upon in situ hybridization for hCAP18 mRNA in epithelial cells (Fig. 2B and 4B and D). In most tissues the signal for hCAP18 mRNA was more prominent in the basal layers of the epithelium and decreased toward the surface (Fig. 2B and 4B), but in cervical tissues found to be dysplastic and inflammatory the strongest expression of hCAP18 mRNA was seen in the upper part of the epithelium toward the surface (Fig. 4D). Sections hybridized with sense RNA probe showed a only background autoradiographic signal (Fig. 2D).
|
|
|
Expression of hCAP18 colocalizes with immunoreactivity for IL-6 in squamous epithelia. Since the gene for hCAP18 contains promoter elements regulated by IL-6, we performed immunohistochemistry with antibodies directed against this cytokine. In all investigated tissues, immunoreactivity for IL-6 colocalized with that for hCAP18 (Fig. 2C and 3D).
| |
DISCUSSION |
|---|
|
|
|---|
In the present investigation we demonstrate that the antimicrobial peptide hCAP18 is expressed at both RNA and protein levels in nonkeratinized squamous epithelia in humans. Most samples showed only minor histopathological signs of inflammation, indicating that there may be a basal constitutive expression of hCAP18 in these tissues. This contrasts with what we previously reported in human skin, where there was no detectable expression of hCAP18 in normal quiescent epidermis although there was a pronounced upregulation in association with a variety of inflammatory conditions (12). One might argue that a continuous expression of antimicrobial activity may be more critical in epithelia lacking an outer keratinized cover. Still, hCAP18 is likely to be a regulated gene, and in the present investigation there was a spatially distinct pattern of hCAP18 production in the cervical samples exhibiting dysplasia and inflammation compared to normal noninflamed tissues (Fig. 4). In the former case, the expression of hCAP18 was clearly upregulated in the superficial layers, creating a striking shield-like band (Fig. 4C to E). Interestingly, in all of the cervical samples, hCAP18 was also detected in scattered stromal cells and in the mucous glands (Fig. 4F and G), indicating that hCAP18 may serve a key role in the defense of this organ.
The complete functional repertoire of hCAP18 remains to be fully elucidated. The C-terminal domain of hCAP18 exhibits potent antibacterial activity in vitro against both gram-positive and gram-negative bacteria, a trait which most likely reflects a major biological role for this protein (18, 20, 28). In addition, several studies have demonstrated that hCAP18 binds to the endotoxin bacterial lipopolysaccharide, neutralizing many of its biological effects (11, 21). Thus, hCAP18 may play a role in the protection against septic shock as was demonstrated in a pig model of endotoxemia (29). Interestingly, the induction of defensins in the trachea is mediated by CD14 on the epithelial cell surface, further supporting a role for epithelial cells in the local host defense (10). Besides direct effects against microbial invasion, it seems conceivable that antibacterial peptides, including hCAP18, serve additional biological roles. Thus, defensins modulate the inflammatory response through the enhancement of chemotaxis, and another peptide, NK lysin, possesses antitumor activity (4). Interestingly, a porcine homologue of hCAP18, PR-39, can induce syndecans in association with wound healing (14). Syndecans are cell surface proteoglycans required for cellular response to growth factors and thereby important in tissue repair. It is plausible that hCAP18 plays a similar role in tissue repair processes in humans.
In all of the tissues there was a striking colocalization between hCAP18 expression and immunoreactivity for IL-6 (Fig. 2 and 3). IL-6 is a proinflammatory cytokine produced by a variety of cell types, including keratinocytes. Typically, the production of IL-6 is induced in response to bacterial products and tissue damage. The regulation of the hCAP18 gene appears to be complex and remains to be fully clarified. However, the identification of several elements responsive to IL-6 in the gene promoter strongly suggests that this cytokine plays a prominent role in modulating the transcription of the hCAP18 gene. Thus, the colocalization of IL-6 and hCAP18 reported here is suggestive of a mechanism through which hCAP18 may be rapidly upregulated in epithelial cells in response to microbial or other challenges.
The existence of immediate and efficient antimicrobial defense systems in epithelial tissues seems both natural and necessary. Epithelia form the borders between the organism and the frequently hostile environment and are continuously exposed to a large variety of potential intruders. Relying solely on the highly evolved but slow adaptive immune system would not be quick enough to stop the invasion, growth, and subsequent takeover by pathogens capable of rapid division. Indeed, there is accumulating evidence that peptide antibiotics are prominent players in the protection of epithelial surfaces. Thus, the expression of hCAP18 was recently demonstrated in airway epithelium, and the peptides human beta defensin 1 and human beta defensin 2 were reported in human skin; the latter was also found to be upregulated by contact with different microorganisms (5, 13, 16). Our findings demonstrate that hCAP18 is widely expressed in squamous epithelia and support the notion of an innate antimicrobial shield at epithelial interfaces. The coexpression of hCAP18 with IL-6 might provide a local mechanism for modulating hCAP18 gene transcription in these tissues.
| |
ACKNOWLEDGMENTS |
|---|
We thank Kerstin Bruce, Anna Hulthén, and Anna-Lena Kastman for excellent technical assistance.
This work was supported by grants from the Karolinska Institute, the Welander-Finsen Foundation, the SSAC Foundation for Research in Antimicrobial Therapy, and the Swedish Psoriasis Association.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Dermatology, Karolinska Hospital, S-17176 Stockholm, Sweden. Phone: 46-8-5177-3348. Fax: 46-8-5177-7851. E-mail: mba{at}hud.ks.se.
Editor: J. R. McGhee
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Agerberth, B. A.,
H. Gunne,
J. Odeberg,
P. Kogner,
H. G. Boman, and G. H. Gudmundsson.
1995.
FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis.
Proc. Natl. Acad. Sci. USA
92:195-199 |
| 2. | Akira, S., H. Isshiki, T. Sugita, O. Tanabe, S. Kinoshita, Y. Nishio, T. Nakajima, T. Hirano, and T. Kishimoto. 1990. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J. 9:1897-1906[Medline]. |
| 3. | Akira, S., Y. Nishio, M. Inoue, X.-J. Wang, S. Wei, T. Matsusaka, K. Yoshida, T. Sudo, M. Naruto, and T. Kishimoto. 1994. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77:63-71[Medline]. |
| 4. | Andersson, M., H. Gunne, B. A. Agerberth, T. Bergman, R. Sillard, H. Jörnvall, V. Mutt, B. Olsson, H. Wigzell, Å. Dagerlind, H. G. Boman, and G. H. Gudmundsson. 1995. NK-lysin, a novel effector peptide of cytotoxic T and NK cells. Structure and cDNA cloning of the porcine form, induction by interleukin 2, antibacterial and antitumour activity. EMBO J. 14:1615-1625[Medline]. |
| 5. |
Bals, R.,
X. Wang,
M. Zasloff, and J. M. Wilson.
1998.
The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface.
Proc. Natl. Acad. Sci. USA
95:9541-9546 |
| 6. | Boman, H. G. 1995. Peptide antibiotics and their role in innate immunity. Annu. Rev. Immunol. 13:61-92[Medline]. |
| 7. | Bos, J. D., and L. Kapsenberg. 1993. The skin immune system: progress in cutaneous biology. Immunol. Today 14:75-78[Medline]. |
| 8. |
Brakenhoff, J. P.,
F. D. de Hon,
V. Fontaine,
E. ten Boekel,
H. Schooltink,
S. Rose-John,
P. C. Heinrich,
J. Content, and L. A. Aarden.
1994.
Development of a human interleukin-6 receptor antagonist.
J. Biol. Chem.
269:86-93 |
| 9. | Cowland, J. B., A. H. Johnson, and N. Borregaard. 1995. hCAP-18, a cathelin/bactenecin like protein of human neutrophil specific granules. FEBS Lett. 368:173-176[Medline]. |
| 10. |
Diamond, G.,
J. P. Russell, and C. L. Bevins.
1996.
Inducible expression of an antibiotic peptide gene in lipopolysaccharide-challenged tracheal epithelial cells.
Proc. Natl. Acad. Sci. USA
93:5156-5160 |
| 11. | Fletcher, M. A., M. A. Kloczewiak, P. M. Loiselle, M. Ogata, M. W. Vermeulen, E. M. Zanzot, and H. S. Warren. 1997. A novel peptide-IgG conjugate, CAP18 106-138-IgG that binds and neutralizes endotoxin and kills gram-negative bacteria. J. Infect. Dis. 175:621-632[Medline]. |
| 12. |
Frohm, M.,
B. A. Agerberth,
G. Ahangari,
M. Ståhle-Bäckdahl,
S. Lidén,
H. Wigzell, and G. H. Gudmundsson.
1997.
The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders.
J. Biol. Chem.
272:15258-15263 |
| 13. | Fulton, C., M. G. Anderson, M. Zasloff, R. Bull, and A. Quinn. 1997. Expression of natural peptide antibiotics in human skin. Lancet 350:1750-1751[Medline]. |
| 14. |
Gallo, R. L.,
M. Ono,
T. Povsic,
C. Page,
E. Eriksson,
M. Klagsbrun, and M. Bernfield.
1994.
Syndecans, cell surface heparan sulfate proteoglycans, are induced by proline-rich antimicrobial peptide from wounds.
Proc. Natl. Acad. Sci. USA
91:11035-11039 |
| 15. | Gudmundsson, G. H., B. A. Agerberth, J. Odeberg, T. Bergman, B. Olsson, and R. Salcedo. 1996. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur. J. Biochem. 238:325-332[Medline]. |
| 16. | Harder, J., J. Bartels, E. Christophers, and J.-M. Schröder. 1997. A peptide antibiotic from human skin. Nature 387:861[Medline]. |
| 17. | Hsu, S. M., L. Raine, and H. Fanger. 1981. Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PA) procedures. J. Histochem. Cytochem. 29:577-580[Abstract]. |
| 18. |
Johansson, J.,
G. H. Gudmundsson,
M. E. Rottenberg,
K. D. Berndt, and B. Agerberth.
1998.
Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37.
J. Biol. Chem.
273:3718-3724 |
| 19. |
Krisanaprakornkit, S.,
A. Weinberg,
C. N. Perez, and B. A. Dale.
1998.
Expression of the peptide antibiotic human -defensin 1 in cultured gingival epithelial cells and gingival tissue.
Infect. Immun.
66:4222-4228 |
| 20. |
Larrick, J. W.,
M. Hirata,
Y. Shimomoura,
M. Yoshida,
H. Zheng,
J. Zhong, and S. C. Wright.
1993.
Antimicrobial activity of rabbit CAP 18-derived peptides.
Antimicrob. Agents Chemother.
37:2534-2539 |
| 21. | Larrick, J. W., M. Hirata, H. Zheng, J. Zhong, D. Bolin, J.-M. Cavaillon, S. H. Warren, and S. C. Wright. 1994. A novel granulocyte-derived peptide with lipopolysaccharide-neutralizing activity. J. Immunol. 152:231-240[Abstract]. |
| 22. | Le, M., and J. Vilcek. 1989. Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab. Invest. 61:588-602[Medline]. |
| 23. |
Schonwetter, B. S.,
E. D. Stolzenberg, and M. A. Zasloff.
1995.
Epithelial antibiotics induced at sites of inflammation.
Science
267:1645-1648 |
| 24. |
Selsted, M. E.,
D. M. Brown,
R. J. DeLange, and R. I. Lehrer.
1983.
Primary structures of MCP-1 and MCP-2, natural peptide antibiotics of rabbit lung macrophages.
J. Biol. Chem.
258:14485-14489 |
| 25. | Steiner, H., D. Hultmark, Å. Engström, H. Bennich, and H. G. Boman. 1981. Sequence and specificity of two antibacterial proteins involved in insect immunity. Nature 292:246-248[Medline]. |
| 26. | Ståhle-Bäckdahl, M., B. D. Sudbeck, A. Z. Eisen, H. G. Welgus, and W. C. Parks. 1992. Expression of 92 kDa type IV collagenase in eosinophils associated with basal cell carcinoma. J. Invest. Dermatol. 99:497-503[Medline]. |
| 27. | Sørensen, O., J. B. Cowland, J. Askaa, and N. Borregaard. 1997. An ELISA for hCAP-18, the cathelicidin present in human neutrophils and plasma. J. Immunol. Methods 206:53-59[Medline]. |
| 28. |
Turner, J.,
Y. Cho,
N. N. Dinh,
A. J. Waring, and R. Lehrer.
1998.
Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils.
Antimicrob. Agents Chemother.
42:2206-2214 |
| 29. | VanderMeer, T. J., M. J. Menconi, J. Zhuang, H. Wang, R. Murtaugh, C. Bouza, P. Stevens, and M. P. Fink. 1995. Protective effects of a novel 32-amino acid C-terminal fragment of CAP18 in endotoxemic pigs. Surgery 117:656-662[Medline]. |
| 30. | Zhao, C., I. Wang, and R. I. Lehrer. 1996. Widespread expression of beta-defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett. 396:319-322[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»